TOR1A and Dystonia: In this study, the human immunodeficiency virus (HIV) protease inhibitor, ritonavir, corrected the variant TOR1A protein mislocalization in vitro and, when administered during an early postnatal period, showed therapeutic effects in a mouse model of DYT-TOR1A, reducing brain irregularities and ameliorating the dystonia phenotype.